A case of a patient with biochemical recurrence and inadequate results of suspected bone metastases in imaging methods - will [68Ga]Ga-PSMA-11 PET/CT give us an answer?
Kacper PełkaAleksandra Bodys-PełkaElżbieta Świątek-RawaKrzysztof TothJolanta KunikowskaPublished in: Nuclear medicine review. Central & Eastern Europe (2023)
We present a case of a 79-year-old asymptomatic patient with prostate adenocarcinoma, Gleason score 9 (4 + 5), with the initial prostate-specific antigen (PSA) level of 17 ng/mL, treated with radiotherapy and hormonotherapy, who was diagnosed with the rapid growth of PSA levels up to 78.8 ng/mL. Due to suspected bone metastases, first, bone scintigraphy was performed. However, it showed only one intense "hot" lesion in the Th7 projection. This image was not consistent with a high level of PSA, for which reason a computed tomography (CT) scan was performed. It revealed lytic metastasis in Th7 and one more suspicious change in L2, which still was inconsistent with the patient's clinical picture. The patient was referred for [68Ga]Ga-PSMA-11 PET/CT. It showed an uncountable number of foci of increased marker accumulation in bones, mostly without visible change in CT examination. This case showed that the clinical results and suspicions of the advancement of a patient's disease are still the most important data in care and therapy planning.
Keyphrases
- pet ct
- positron emission tomography
- prostate cancer
- computed tomography
- case report
- magnetic resonance imaging
- dual energy
- image quality
- squamous cell carcinoma
- healthcare
- contrast enhanced
- early stage
- chronic pain
- machine learning
- magnetic resonance
- high resolution
- artificial intelligence
- radiation induced
- health insurance
- quantum dots
- sensitive detection
- photodynamic therapy
- postmenopausal women
- loop mediated isothermal amplification